![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 53, 37591-37597, December 31, 1999
,
,From the Centre de Recherche en Cancérologie de l'Université Laval, Québec G1R 2J6, Canada
| |
ABSTRACT |
|---|
|
|
|---|
The stress-activated protein kinase 2 (SAPK2/p38)
is activated by various environmental stresses and also by a vast array of agonists including growth factors and cytokines. This implies the
existence of multiple proximal signaling pathways converging to the
SAPK2/p38 activation cascade. Here, we show that there is a sensing
mechanism highly specific to heat shock for activation of SAPK2/p38.
After mild heat shock, cells became refractory to reinduction of the
SAPK2/p38 pathway by a second heat shock. This was not the result of a
toxic effect because the cells remained fully responsive to reinduction
by other stresses, cytokines, or growth factors. Neither the activity
of SAPK2/p38 itself nor the accumulation of the heat shock proteins was
essential in the desensitization process. The cells were not
desensitized to heat shock by other treatments that activated
SAPK2/p38. Moreover, inhibiting SAPK2/p38 activity during heat shock
did not block desensitization. Also, overexpression of HSP70, HSP27, or
HSP90 by gene transfection did not cause desensitization, and
inhibiting their synthesis after heat shock did not prevent
desensitization. Desensitization rather appeared to be linked closely
to the turnover of a putative upstream activator of SAPK2/p38.
Cycloheximide induced a progressive and eventually complete
desensitization. The effect was specific to heat shock and minimally
affected activation by other stress inducers. Inhibiting protein
degradation with MG132 caused the constitutive activation of SAPK2/p38,
which was blocked by a pretreatment with either cycloheximide or heat
shock. The results thus indicate that there is a sensing pathway highly
specific to heat shock upstream of SAPK2/p38 activation. The pathway
appears to involve a short lived protein that is the target of rapid
successive up- and down-regulation by heat shock.
Exposure of mammalian cells to heat stress induces two major
signaling events, the transcriptional activation of genes coding for
the heat shock proteins
(HSP(s))1 (1-3) and the
activation of the MAP kinases, including ERK, SAPK1/JNK, and SAPK2/p38
(4-6). At the cellular level, the treatment results in a tremendous
transient increase in resistance to a subsequent heat stress, a process
termed thermotolerance (7). The role of the transcriptional activation
of the HSP genes in the acquisition of thermotolerance has been
suggested by the demonstration that HSP accumulation after mild
triggering heat shock closely parallels development of thermotolerance,
both responses culminating 5-10 h after the priming treatment (8-10).
Also, gene transfection studies have shown that overexpression of
individual HSP (e.g. HSP70 or HSP27) confers resistance
against thermal injury and increases cell survival (11-14). When
overexpressed, both HSP70 and HSP27 act as inhibitors of apoptosis and
protect cells against a variety of toxic treatments (15-25).
There is evidence for a role of each of the MAP kinase cascades in the
cell response to stress and apoptosis signaling. SAPK1/JNK and
SAPK2/P38 activities were in most cases associated with promotion of
apoptosis, whereas ERK activity is in general associated with protection (26). In some circumstances, however, SAPK1/JNK and SAPK2/p38 can have a protective function (27-29). Activation of SAPK2/p38 appears particularly significant in the case of heat shock
because one of the heat shock proteins, HSP27, is phosphorylated by
MAPKAP kinase-2, a physiological substrate of SAPK2/p38 (6, 30).
SAPK2/p38-mediated phosphorylation has been shown to be essential for
some activities of HSP27. Upon phosphorylation, high molecular weight
HSP27 multimers dissociate into monomers and dimers providing a pool of
active monomeric HSP27 which can modify the dynamics of actin filaments
(31, 32). This activity results in the stabilization of the
microfilaments in response to oxidative stress (33-35). However,
strong activation of SAPK2/p38 and phosphorylation of HSP27 coupled
with a high level of expression of HSP27 can also in some circumstances
result in bleb formation and increased toxicity, illustrating the
necessity of a tight control over SAPK2/p38 activation (36).
HSP27 becomes phosphorylated within 20 min upon exposure of cells to
elevated temperature (10). Phosphorylation is maximal immediately or
soon after the triggering heat shock and returns to the control level
after 5 h when cells are fully thermotolerant. Intriguingly, HSP27
is not phosphorylated when a second heat shock is applied during
thermotolerance. Desensitization starts at 2 h after the priming
treatment, peaks at 5 h, at which time no reinduction of HSP27
phosphorylation is observed, and vanishes by 15 h. In fact, a
perfect temporal correlation has been found between the capacity of the
cells to resist HSP27 phosphorylation and the thermotolerant state.
This has led to the suggestion that some factors induced by the priming
heat shock and generated along with the development of thermotolerance
block the signaling pathway leading to HSP27 phosphorylation (10).
In the present study, we investigated the mechanisms responsible for
inhibiting HSP27 phosphorylation in heat-induced thermotolerant cells.
The results showed that the desensitization process occurs at a
proximal step in the signaling pathway upstream of SAPK2/p38 phosphorylation and activation. Desensitization was strictly homologous affecting exclusively heat shock induction of the SAPK2/p38 pathway. We
infer that there is a sensing mechanism highly specific to heat shock
in the activation pathway of SAPK2/p38, and we showed that it involves
a short lived protein whose activity depends on a tight regulation
between synthesis and degradation.
Materials--
[ Antibodies--
Anti-HA is a mouse monoclonal antibody
recognizing the YPYDVPDYA peptide sequence from human influenza
hemagglutinin protein (Roche Molecular Biochemicals Corporation). All
other antibodies used are polyclonal antibodies raised in rabbit.
Anti-GST-MAPKAP kinase-2 recognizes the p45 and p54 isoforms of MAPKAP
kinase-2 (30); anti-p38, SAPK2/p38 (34); L2R3, the Chinese hamster HSP27 (33); anti-HSP70 (no. 799), the inducible form of HSP70 (39);
anti-HSP90 Cell Culture and Treatments--
Chinese hamster CCL39 and human
HeLa cells were cultivated in Dulbecco's modified Eagle's medium
containing 2.2 g/liter NaHCO3 and 4.5 g/liter glucose, and
supplemented with 5% or 10% fetal bovine serum, respectively.
Cultures were maintained at 37 °C in a 5% CO2
humidified atmosphere. Exponentially growing cells (106
cells/60 × 15-mm culture dish plated the day before the
experiment) were used for all treatments except for mitogenic
stimulation where serum-starved cells, deprived for 24 h, were
used. For heat shock treatment, the dishes were sealed with Parafilm
and immersed into a circulating water bath thermoregulated at 44 ± 0.05 °C for the indicated period of time. All other inducers used
were added directly into culture medium, and cells were maintained at
37 °C for the duration of treatments.
Transfection--
The plasmids pSVHa27WT (31), Immunoprecipitation--
After treatments, cells were scraped
and extracted in lysis buffer containing 20 mM MOPS, pH
7.0, 10% glycerol, 80 mM Kinase Assays--
Kinase activities were assayed in immune
complexes. MAPKAP kinase-2 activity was measured using 1 µg of
recombinant HSP27 as substrate (30). The assays were carried out in 25 µl of kinase buffer K (100 µM ATP, 3 µCi of
[ Western Blot Analysis--
Proteins were separated through 10%
SDS/polyacrylamide gels and transferred onto nitrocellulose as
described previously (33). After reacting the membranes with the
specific antibodies, proteins were detected using an ECL detection kit
(Amersham Pharmacia Biotech) or by iodinated secondary antibodies and
quantified using PhosphorImager analysis.
Desensitization of MAPKAP Kinase-2 and SAPK2/p38 Activation by Heat
Shock--
Cells that had become thermotolerant after a mild heat
shock are refractory to heat-induced phosphorylation of HSP27 (10). We
investigated whether desensitization could be correlated with the loss
of responsiveness of MAPKAP kinase-2 and SAPK2/p38, the two upstream
activators of HSP27 phosphorylation. In CCL39 cells, MAPKAP kinase-2
and SAPK2/p38 are activated maximally right after a 20-min heat shock
(Fig. 1, A and
B). The activities of both kinases rapidly
returned to basal level within the next 3-5 h. This is in perfect
agreement with the previously published kinetics of HSP27
phosphorylation, which is maximal within 20 min and is back to normal
basal levels within 3-5 h after the priming treatment (10). We
examined the reactivation of these two kinases by heat shock at various
times after a priming heat shock treatment. Neither kinase was
reactivated when the cells were restimulated at any time between 5 and
10 h postpriming although both were present at normal levels as
determined by immunoblot using anti MAPKAP kinase-2 and SAPK2/p38
antibodies (Fig. 1C). At later times (24 h), both kinases
were activated normally as shown previously for HSP27 phosphorylation
(10). Similar kinetics of desensitization was observed in HeLa cells
(data not shown). In the case of SAPK2/p38, the results were confirmed
using a phospho-specific antibody, which indicated that the failure to
activate SAPK2/p38 correlated with lack of phosphorylation by the
upstream kinases (data not shown). The desensitization appeared to be
total and not just a mere displacement in the dose-response curve for
heat shock. Whereas a 20-min heat shock induced a maximal MAPKAP
kinase-2 activation in naive cells, treatment for up to 1 h did
not induce MAPKAP kinase-2 activity in fully desensitized cells (Fig.
1D).
Activation of SAPK2/p38 and MAPKAP Kinase-2 by Heterologous Stimuli
in Heat-desensitized Cells--
The Western blot analysis shown in
Fig. 1C indicated that heat-induced desensitization of
MAPKAP kinase-2 and SAPK2/p38 activation were not caused by a
down-regulated expression of MAPKAP kinase-2 or SAPK2/p38 in
thermotolerant cells. To determine whether these enzymes were
physically available and functional, we evaluated if the
desensitization process also affected MAPKAP kinase-2 activation by
other known activators of the pathway. Cells were first exposed to heat
shock and then restimulated with various growth factors, cytokines, or
stress agents. In control cells, thrombin and TNF- Desensitization Does Not Require SAPK2/p38 Activity--
Having
shown clear homologous desensitization of the SAPK2/p38 pathway
activation by heat shock, we next tested if other agonists were also
capable of eliciting a desensitization to heat shock. Cells pretreated
with EGF showed virtually total desensitization of MAPKAP kinase-2
activation to restimulation with EGF (Fig. 3A). MAPKAP kinase-2
activation was not induced above the residual level remaining after the
first stimulation. In contrast, heat shock induction was unaffected in
EGF-desensitized cells. Similarly, thrombin treatment induced
homologous desensitization of MAPKAP kinase-2 activation but did not
desensitize to heat shock (Fig. 3B). One conclusion of these
results is that activation of SAPK2/p38 is not a sufficient condition
for heat desensitization. The possibility that it could be required
during heat-induced homologous desensitization was tested by
determining the effect on heat-induced desensitization of SB203580, a
pyridinil imidazol derivative that efficiently inhibits SAPK2/p38
activity (43). As reported previously, SB203580 did not prevent
SAPK2/p38 activation but led to a total inhibition of MAPKAP kinase-2
activation (Fig. 4) and HSP27
phosphorylation. Inhibition of SAPK2/p38 activity during the priming
heat shock treatment had no effect on induction of desensitization,
indicating that events occurring downstream of SAPK2/p38 were not
required for inducing homologous heat desensitization.
HSP90, HSP70, or HSP27 Accumulated during Development of
Thermotolerance Is Not Implicated in Heat-induced Homologous
Desensitization--
Another possibility for explaining the
heat-induced desensitization is that one of the heat shock proteins
that accumulate after the first heat shock acts as a repressor of one
of the elements in the heat-specific sensing pathway that triggers
SAPK2/p38 activation. This appeared unlikely because the kinetics of
accumulation of the HSP after heat shock does not match the kinetics of
desensitization. For example, HSP27 and HSP70 concentrations peak at 10 and 14 h after heat shock, whereas desensitization is maximal at
5 h (10). Nevertheless, we tested directly the effect of
overexpressing HSP70, HSP90, or HSP27 on heat activation of SAPK2/p38.
HSP70, HSP90, or HSP27 was cotransfected with HA-tagged SAPK2/p38 in CCL39 cells. Under the conditions of transfection used, we calculated, after correcting for the transfection efficiency (about 20%), that
individual transfected cells expressed amounts of HSP equivalent (HSP70
and HSP90) or 2-fold higher (HSP27) than what control cells express
5 h after heat shock. Epitope-tagged SAPK2/p38 was
immunoprecipitated from the transfected cells at various times after
shifting the temperature to 44 °C, and p38 activity was determined
using ATF2-GST as substrate. As shown in Fig.
5A overexpression of HSP90,
HSP70, or HSP27 had no effect on heat activation of SAPK2/p38 compared with cells transfected with an empty vector. Furthermore, these cells
were desensitized to heat shock to the same extent as control cells
(Fig. 5B). These results strongly suggested that HSP70, HSP90, or HSP27 generated during development of thermotolerance was not
implicated in heat-induced homologous desensitization of SAPK2/p38
activation. This was supported further by the finding that the addition
of cycloheximide during and after heat shock to inhibit HSP and total
protein synthesis did not block desensitization of the SAPK2/p38
pathway (see below).
A Short Lived Protein Regulates SAPK2/p38 Activation by Heat
Shock--
Cycloheximide desensitized MAPKAP kinase-2 to activation by
heat shock (Fig. 6A). The
capacity to activate MAPKAP kinase-2 with heat shock decreased
progressively upon exposure to cycloheximide and was totally inhibited
after 5 h, suggesting the existence of an essential element with a
half-life in the order of 2-3 h in the SAPK2/p38 activation pathway.
To determine whether this element was specific to heat shock, cells
were exposed to cycloheximide for 5 h and then treated with
H2O2, sodium arsenite, or sorbitol. In contrast
to heat shock, activation of MAPKAP kinase-2 by these agents was not or
only slightly affected by the cycloheximide pretreatment
(Fig. 6B). Similar results were
obtained using two other structurally and mechanistically unrelated
inhibitors of protein synthesis, puromycin and emetine. Preincubation
with these agents also blocked activation of the p38 pathway by heat shock but not by hyperosmotic shock (Fig.
6C). This indicated that the putative short lived
protein was a proximal element of the heat shock response pathway and
was not required for these inducers. To investigate further the
hypothesis of a short lived regulator, we looked at the effects of the
proteasome inhibitor MG132 on SAPK2/p38 activation. As reported before
(44), MG132 induced a robust activation of SAPK2/p38 which developed to
maximal level within 5 h. In contrast to SAPK2/p38 activation by
other inducers, activation by MG132 was not transient and was maintained for as long as MG132 was present in the medium for up to
24 h (Fig. 7, top
panel). At longer times, MG132 was toxic. Pretreating cells with
cycloheximide or heat shock prevented MG132 activation of SAPK2/p38
(Fig. 7, lower panels), suggesting
that a protein that was up-regulated by MG132 and responsible for
SAPK2/p38 activation was degraded during prolonged treatment with
cycloheximide or after heat shock.
SAPK2/p38 is activated in mammalian cells by diverse agents
including chemical and physical stresses such as heat shock, oxidants, hyperosmolarity, and also numerous cytokines and growth factor agonists
(for review, see Ref. 45). Hence multiple sensing pathways exist which
must eventually converge on the main signaling elements of SAPK2/p38.
Two MAP kinase kinases, MKK3 and MKK6, have been shown to phosphorylate
and activate SAPK2/p38 selectively (38, 46-48), and several different
MAP kinase kinase kinases including MLK-2 and -3, MEKK1, ASK1, and TAK1
(48-51) can potentially activate MKK3 or MKK6. The MAP kinase kinase
kinases are themselves activated either by kinases of the ste-20-like
family of protein kinases or more directly by interacting with adaptors
of specific receptors (for review, see Ref. 45). Ligation of Fas to its
ligand, for example, recruits the adaptor Daxx yielding to the
activation in cascade of ASK1, MKK6, and SAPK2/p38 (52).
H2O2 and TNF- This work stemmed from a previous observation that cells that have
developed thermotolerance as a result of a short exposure to mild heat
shock are refractory to induction of HSP27 phosphorylation by a second
triggering heat shock (10). Here we showed that the failure to reinduce
phosphorylation of HSP27 is accompanied by a failure to activate the
HSP27 kinase, MAPKAP kinase-2, and to phosphorylate and activate the
MAPKAP kinase-2 activator, SAPK2/p38. This temporary refractoriness to
restimulation was specific to heat shock and did not interfere with
activation by all of the growth factors, cytokines, and stressing
agents tested. This implies that heat desensitization is not the result
of heat-induced alterations in MAPKAP kinase-2, SAPK2/p38, or any
upstream signaling molecules that are also used by growth factors,
cytokines, or other stress. Pathways connecting receptors/sensors for
growth factors, cytokines, or other stress to the common signaling
components essential for MAPKAP kinase-2 activation were not
desensitized and were still functional in heat-desensitized cells. Only
components specific to heat shock signaling were altered, implying that
such components do exist and play the role of a heat shock sensor. The
heat-desensitized element must lie upstream of SAPK2/p38 and upstream
of the converging point of the various pathways that lead to activation
of SAPK2/p38. It also must lie between the heat shock "sensor" and
the diverging point leading to activation of SAPK1/JNK and SAPK2/p38
because SAPK1/JNK activation is also homologously desensitized by heat shock in the CCL39 cell line used in this study (data not shown) and in
other cell lines (23, 58, 59).
Very little is known concerning the mechanisms by which stress
activates signaling pathways in mammalian cells. In the case of
oxidative stress, oxidation of thioredoxin, a direct inhibitor of ASK1,
and dimerization of ASK1 lead to activation of kinases upstream of
SAPK2/p38 (53, 60). In the case of UV light and hyperosmotic shock,
activation of the SAPK1/JNK signal transduction pathway and activation
of new gene activity result from the perturbation of the cell membrane
inducing conformation changes in receptors. These agents induce
activation, clustering, and internalization of the receptors for EGF,
TNF- Several mechanisms have been demonstrated for homologous
desensitization of receptor-mediated responses to agonists including direct down-regulation of the receptor expression and feedback inhibition of essential signaling components by phosphorylation or
other mechanisms. We clearly showed that heat-induced homologous desensitization of HSP27 phosphorylation is not caused by
down-regulation of MAPKAP kinase-2 or SAPK2/p38 expression. Both
upstream regulators of HSP27 phosphorylation were expressed at normal
levels in heat-desensitized cells and could be activated by other
stress, growth factors, and cytokines. We also showed that inhibition
of SAPK2/p38 during the priming treatment had no effect on the heat
desensitization process, indicating that heat-induced homologous
desensitization is not the result of a negative feedback loop involving
activation of SAPK2/p38. This is consistent with the results that EGF
and thrombin also induced SAPK2/p38 without desensitizing the cells to
heat shock.
Homologous heat-induced desensitization of HSP27 phosphorylation occurs
coincidentally with HSP accumulation (10), but none of the HSP tested
inhibited the activation of p38 nor the process of heat-induced
homologous desensitization in CCL39 cells. Our results contrast with
those of Mosser et al. (58) and Gabai et al.
(29), who found that extremely high (100-fold) overexpression of HSP70
blocked activation of SAPK1/JNK and SAPK2/p38 by a variety of stressful
conditions in PEER cells. They are however consistent with other
observations by the same (58) and other authors (10, 18, 23, 24),
indicating that permanent cell lines constitutively expressing either
HSP27 or HSP70 genes respond normally or even slightly better to heat
induction of HSP27 phosphorylation or activation of SAPK1/JNK than
control cells. In WEHI and RIN cells, we also found that overexpression
of HSP70 either in a permanent cell line or in transient transfection
assays enhanced (2-fold) induction of SAPK2/p38 by cytokines and had
only a slight inhibitory effect on heat
shock.3 The reason for the
variable results obtained with HSP70 is not clear but may reflect the
existence of distinct pathways for induction of SAPK1/JNK and SAPK2/p38
by stress. One pathway may be triggered as a consequence of damages
caused by heat shock. During apoptosis, for example, damages can
activate caspases, which in turn can activate SAPK1/JNK and SAPK2/p38
thereby activating even more caspase activities in a loop of
amplification (64-66). In that situation, the capacity of HSP70 to
block apoptosis downstream of caspase activation (24) would also result
in blocking SAPK activation. A second pathway involving a more specific
heat shock sensing mechanism independent of HSP70 may prevail during
nontoxic heat shock treatment.
Results obtained with cycloheximide and MG132 suggest a possible
mechanism for activation of SAPK2/p38 by heat shock and for homologous
heat desensitization. We found that pretreatment with cycloheximide
progressively blocks SAPK2/p38 activation by heat shock. This finding
suggests that an essential component of the SAPK2/p38 activation
pathway is short lived and rapidly eliminated during pretreatment with
cycloheximide. This component is, however, essential only in the heat
shock activation pathway because cycloheximide treatments do not
interfere or interfere only slightly with activation by hydrogen
peroxide, sorbitol, or sodium arsenite. We also found that MG132, an
inhibitor of proteasome function, caused a sustained activation of
SAPK2/p38. This suggests that accumulation of a normally rapidly
degraded protein acts as a positive regulator of the SAPK2/p38 pathway.
The finding that cycloheximide-pretreated cells do not respond to MG132
supports the view that this regulator is rapidly turning over under
normal conditions and thus in tight equilibrium between rapid synthesis
and rapid degradation. Heat shock-desensitized cells failed to respond
to MG132, indicating that this regulator is also eliminated after heat
shock. In mammalian cells, 80-90% of the protein breakdown including
short and long lived proteins occurs by the ubiquitin-proteasome
pathway (67). Upon heat shock, accumulation of unfolded proteins causes
an initial overload of the ubiquitin-proteasomal system, a decrease in
the free-ubiquitin pool, and a transient accumulation of short
half-life protein normally degraded by this system (68, 69). Thus, we hypothesize that like MG132, heat shock causes an accumulation of this
upstream activator of SAPK2/p38. In contrast to MG132, which maintains
this factor at a high concentration and thus keeps SAKP2/p38 activated,
the accumulation of the factor is only transient in the case of heat
shock. Several mechanisms can contribute to the rapid disappearance of
the factor after returning cells to normal temperature. The general
protein synthesis rate is decreased after heat shock in mammalian
cells (70); ubiquitin is itself a heat shock protein, and its
concentration is increased after heat shock (71); an increased
concentration of HSP70 and/or HSP90, which under some conditions may
facilitate protein degradation by proteasomes, can contribute to
accelerate protein degradation transiently (72, 73).
In conclusion, we have shown that heat shock-induced desensitization of
the SAPK2/p38 pathways occurs through a specific and regulated manner
involving a rapidly turning-over activator located at a proximal step
of the activation cascade. Desensitization affected only the heat shock
activation pathway pointing out at the existence of a specific sensing
pathway for heat shock, distinct from pathways used by other stresses,
growth factors and cytokines.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
32-P]ATP (3,000 Ci/mmol) was
purchased from NEN Life Sciences Products.
H2O2, MG132
(N-carbobenzoxyl-Leu-Leu-norleucinal), cycloheximide,
emetine, puromycin, and EGF were from Sigma Chemical Co. Thrombin was
from Life Technologies, Inc. TNF-
and SB203580 were from Calbiochem.
Recombinant HSP27 and ATF2-GST were purified from Escherichia
coli transformed with appropriate plasmids (37, 38). Chemicals for
electrophoresis were obtained from Bio-Rad and Fisher Scientific.

(no. 214), the
and
forms of
HSP902; and phospho-p38MAPK,
the phosphorylated and activated form of SAPK2/p38 (New England Biolabs).
APrhsp70 (40),
and pcDNA3-HA-p38 (41) were used for expression of Chinese hamster
HSP27, inducible human HSP70, and HA-tagged SAPK2/p38, respectively. pAM-HSP90
contains the human HSP90
cDNA (42) inserted at the SalI site of the expression vector pALTER-MAX (Promega).
CCL39 cells were plated 24 h before transfection at a
concentration of 0.75 × 106cells/75 cm2
culture flask. Transfection by calcium phosphate precipitation was done
as described before using 21 µg of plasmid (7 µg of
pcDNA3-HA-p38 and 14 µg of pSVHa27WT,
APrhsp70, PAM-HSP90, or
carrier DNA) per flask (11). The cells were replated 24 h later
and used 48 h after transfection.
-glycerophosphate, 5 mM EGTA, 0.5 mM EDTA, 1 mM
Na3VO4, 5 mM
Na4P2O7, 50 mM NaF, 1%
Triton X-100, 1 mM benzamidine, 1 mM
dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride. The
extracts were vortexed and centrifuged at 17,000 × g
for 12 min at 4 °C. The clarified supernatants were either used
immediately for immunoprecipitation or stored at
80 °C. The
further steps were carried out at 4 °C. The supernatant was diluted
four times in buffer I (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 1 mM EGTA, 1 mM MgCl2, 1 mM
Na3VO4, 1% Triton X-100, and 1 mM
phenylmethylsulfonyl fluoride). Antibodies were added in limiting
concentrations, and the mixtures were incubated for 1 h. 10-15
µl of protein A-Sepharose (Amersham Pharmacia Biotech) 50% v/v in
buffer I were added, and the mixtures were incubated for 30 min.
Samples were centrifuged for 15 s and washed three times with 300 µl of buffer I. Immunoprecipitates were used directly for the kinase assays.
32-P]ATP, 40 mM p-nitrophenyl
phosphate, 20 mM MOPS, pH 7.0, 10% glycerol, 15 mM MgCl2, 0.05% Triton X-100, 1 mM
dithiothreitol, 1 mM leupeptin, 0.1 mM
phenylmethylsulfonyl fluoride, and 0.3 µg of protein kinase A
inhibitor). The kinase activity was assayed for 30 min at 30 °C and
was stopped by the addition of 10 µl of SDS-polyacrylamide gel
electrophoresis loading buffer. Immunoprecipitated SAPK2/p38 was
assayed analogously using ATF2-GST as substrate (34). The kinase assay
buffer for SAPK2/p38 contained 50 mM HEPES, pH 7.4, 50 mM
-glycerophosphate, 50 mM
MgCl2, 0.2 mM Na3VO4, 2 µg ATF2-GST, and 4 µCi of [
32-P]ATP. Kinase
activities were evaluated by measuring incorporation of the
radioactivity into the specific substrates after resolution by
SDS-polyacrylamide gel electrophoresis and quantification using PhosphorImager (Molecular Dynamics). To ensure equal loading of the
kinases on different lanes, immune complexes were analyzed by Western
blotting using specific antibodies.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (36K):
[in a new window]
Fig. 1.
Heat shock-induced homologous desensitization
of the SAPK2/p38 pathway. Exponentially growing CCL39 cells were
heat shocked at 44 °C for 0 (no treatment, NT) or 20 min
(first heat shock, HS1). At varying times (
t)
thereafter the cells were submitted to a second heat shock of 0 or 20 min at 44 °C (second heat shock, HS2). Immediately after
the second treatment, extracts were prepared and processed to
determined MAPKAP kinase-2 (panel A) and SAPK2/p38
(panel B) activities in immune complexes using recombinant
HSP27 and ATF2-GST as substrate, respectively. Proteins were then
separated by SDS-polyacrylamide gel electrophoresis, and kinase
activities were visualized by autoradiography of the
32P-labeled substrates. Panel C, at varying time
points after heat shock, 20 µg of total cell extract proteins was
also analyzed by Western blot using anti-GST MAPKAP kinase-2 (to detect
both p45 and p54 MAPKAP kinase-2 isoforms) and anti-p38 antibodies.
Panel D, cells were submitted to a 20-min heat shock at
44 °C (
,
) or left untreated (
) and 5 h later exposed
to a second heat shock for varying lengths of times at 44 °C (
,
) or 37 °C (
). After treatments, MAPKAP kinase-2 activity was
determined. Results are expressed as the ratio of the kinase activities
of stimulated cells over the activity of unstimulated cells.
elicited a strong
activation of MAPKAP kinase-2 (Fig.
2,A and B). The
ability of thrombin and TNF-
to activate MAPKAP kinase-2 was
unaffected in heat-desensitized cells. Similarly, heat-desensitized cells remained fully responsive to restimulation with all other agonists tested at 5 h after heat shock, namely EGF,
platelet-derived growth factor, readdition of serum to serum-deprived
cells, sphingomyelinase, and phorbol ester (data not shown). The
ability of physical or chemical stresses to activate the SAPK2/p38
pathway in heat-desensitized cells was also tested by looking either
directly at the activity of SAPK2/p38 or at the activity of MAPKAP
kinase-2. Both H2O2 and sodium arsenite induced
a normal activation of the pathway at all times after the desensitizing
heat shock (Fig. 2, C and D). Similarly, sorbitol
induction of the pathway was about 75% of the control response at
5 h after the priming heat shock (data not shown). Hence heat
shock-induced desensitization of the SAPK2/p38 pathway was not caused
by a general toxic response and affected specifically the heat
shock-sensitive pathway. Thus, the failure to induce phosphorylation of
HSP27 in heat-induced thermotolerant cells was the result of a total
inhibition of some proximal elements of the heat shock signaling
pathway preventing phosphorylation and activation of SAPK2/p38 and
activation of the HSP27 kinase MAPKAP kinase-2.

View larger version (36K):
[in a new window]
Fig. 2.
Activation of the SAPK2/p38 pathway by
thrombin, TNF-
, H2O2,
and sodium arsenite in heat-desensitized cells. CCL39
(panels A, C, and D) or HeLa
(panel B) cells were serum-starved for 24 h
(panels A and B) or maintained in
normal serum-containing medium (panels C and
D) and then exposed to 0 (nontreated,
NT) or a 20-min heat shock (HS) at 44 °C
(panels A, C, and D) 43.5 °C
(panel B). At varying times (
t) thereafter,
the cells were left untreated (NT) or exposed for 5 min to
thrombin (1unit/ml, THR), 15 min to TNF-
(20 ng/ml),
60-min to H2O2 (1 mM), or 60 min to
sodium arsenite (200 µM, ARS). Cells extracts
were prepared at the end of the treatments, and MAPKAP kinase-2
(panels A, B, and C) or SAPK2/p38
(panel D) activities were assayed using recombinant HSP27 or
ATF2-GST as substrates, respectively.

View larger version (45K):
[in a new window]
Fig. 3.
Activation of MAPKAP kinase-2 by heat shock
is not affected in EGF- or thrombin-desensitized cells. Cultures
of CCL39 cells were serum starved for 24 h and then exposed to a
5-min EGF treatment (2.5 ng/ml) (panel A) or a 5-min
thrombin treatment (1unit/ml, THR) (panel B).
Some cells were left untreated (NT). At varying times
(
t) thereafter, the cells were left untreated or
submitted to a second identical treatment with EGF or thrombin or
submitted to a 20-min heat shock at 44 °C (HS). Cells
extracts were prepared at the end of the treatments, and MAPKAP
kinase-2 activity was assayed using recombinant HSP27 as
substrate.

View larger version (18K):
[in a new window]
Fig. 4.
Heat desensitization does not require
SAPK2/p38 activity. Panel A, exponentially growing
CCL39 cells were pretreated (+SB) or not (
SB)
for 1 h with the SAPK2/p38 inhibitor SB203580 (5 µM)
and then exposed (HS) or not (Ctl) to a 20-min
heat shock at 44 °C before being extracted. Panel B,
cells were pretreated (+SB) or not (
SB) for
1 h with SB203580 (5 µM), exposed to a 20-min heat
shock at 44 °C, and returned at 37 °C. 5 h later, the cells
were exposed (HS) or not (Ctl) to a second
identical heat shock before being extracted. Extracts were assayed for
MAPKAP kinase-2 (black bars) or SAPK2/p38 (white
bars) activities using recombinant HSP27 or ATF2-GST as
substrates, respectively. Results are expressed as the ratio of the
kinase activities of stimulated cells over the activity of unstimulated
cells.

View larger version (50K):
[in a new window]
Fig. 5.
Overexpression of HSP90, HSP70, or HSP27 is
not involved in heat-induced homologous desensitization. CCL39
cells were transfected with the HA-tagged p38 vector together with
HSP90, HSP70, HSP27, or empty pSVT7 vectors. Panel
A, epitope-tagged SAPK2/p38 was immunoprecipitated from the
transfected cells at various times after shifting the temperature from
37 to 44 °C, and SAPK2/p38 activity was determined using ATF2-GST as
substrate. Panel B, the transfected cells were exposed (+)
or not (
) to a priming heat shock (HS1) and 5 h later
exposed (+) or not (
) to a second heat shock (HS2). Both
heat shock treatments were for 20 min at 44 °C. Epitope-tagged
SAPK2/p38 was immunoprecipitated, and SAPK2/p38 activity was determined
using ATF2-GST as substrate.

View larger version (30K):
[in a new window]
Fig. 6.
Protein synthesis inhibitors desensitize the
activation of the SAPK2/p38 pathway by heat shock but not by other
stresses. Panel A, exponentially growing CCL39 cells
were incubated in the presence of 100 µg/ml cycloheximide for
different periods of time (1-5 h) before being submitted (+,
HS) or not (
, C) to a 20-min heat shock at
44 °C. Panel B, cells were preincubated (+) or not (
)
with 100 µg/ml cycloheximide for 5 h (CHX) prior to
being exposed to H2O2 (5 mM, 15 min), sorbitol (SO, 0.3 M, 15 min), or sodium
arsenite (Ars, 200 µM, 60 min). Panel
C, cells were preincubated with puromycin (50 µg/ml), emetine (5 µM), or left untreated (
) for 5 h prior to being
exposed to heat shock or sorbitol. At the end of treatments, MAPKAP
kinase-2 (panels A and B) or SAPK2/p38
(panel C) activities were determined using recombinant HSP27
or ATF2-GST as substrate. In panel A, the results are
presented as the ratio of the kinase activities of stimulated cells
over the activity of unstimulated cells.

View larger version (19K):
[in a new window]
Fig. 7.
SAPK2/p38 activation by MG132 is blocked by
cycloheximide and heat shock. Control (
),
cycloheximide-pretreated (
), or heat shock-pretreated (
) CCL39
cells were incubated with 5 µM MG132 for the indicated
time periods. At the end of the treatments, SAPK2/p38 activity was
determined using ATF2-GST as substrate. Pretreatment with cycloheximide
was for 5 h at a concentration of 100 µg/ml (cycloheximide was
left in the medium during exposure to MG132). Preheat shock consisted
of a 20-min exposure at 44 °C administered 4 h before MG132.
Results are expressed as the ratio of the kinase activities of
stimulated cells over the activity of unstimulated control cells.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
also use ASK1 to activate
SAPK2/p38, but in this case the signal is generated through the
oxidative stress sensor thioredoxin, which acts as a regulator of ASK1
(53). TAK1 may mediate activation of SAPK2/p38 after interaction either
with the ste-20-like protein HPK in the case of EGF and transforming
growth factor
(54, 55), or HGK in the case of TNF-
activation
(56). G-proteins mediate activation of SAPK2/p38 by agonists of
serpentine receptors, but the molecules coupling G-proteins to the
SAPK2/p38 pathway are still unknown (57). The proximal signaling events
activated by heat and the signaling mechanism that leads to heat shock
activation of the SAPK2/p38 cascade are also unknown.
, and interleukin-1 and the assembly of signaling molecules at
these receptors (61). Agonist-independent phosphorylation and
activation of the EGF receptor also seem to be involved in the
activation of the MAP kinase ERK by heat shock. However, activation of
MAPKAP kinase-2 by heat shock is not blocked by tryphostin AG1478, a
selective EGF receptor inhibitor, nor by a dominant negative mutant of
EGF receptor (62), and there is no cross-desensitization of the
SAPK2/p38 pathway between heat shock and EGF (this study), suggesting
that activation of SAPK2/p38 uses a sensing pathway different from ERK.
There is also no cross-desensitization between heat shock and thrombin,
and we found that the heat-desensitized component is not required for
transmitting signal from growth factor and cytokine receptors to MAPKAP
kinase-2, strongly suggesting that heat shock does not use proximal
elements of these pathways for triggering SAPK2/p38. All of these
results contribute to the conclusion that a specific receptor/sensor
pathway is used by heat shock to activate the SAPK2/p38 pathway. It
should also be added that the pathway is unlikely to use a
membrane-bound molecule because suramin, an extracellular antagonist of
several membrane receptors, did not block heat shock activation of p38
but it completely blocked activation of ERK by heat shock and also
induction of ERK and SAPK1/JNK by UV light and hyperosmotic shock
(61-63). Moreover, it was also reported that a low concentration of
the anionic detergent Triton X-100, which totally inhibited activation
of SAPK1/JNK by UV light, did not prevent activation of p38 by heat
shock (5).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. R. M. Tanguay for providing
antibodies against HSP70 and HSP90, and Drs. D. D. Mosser and J. Moscat for plasmids
APrhsp70 and pcDNA3-HA-p38, respectively.
| |
FOOTNOTES |
|---|
* This study was supported in part by Medical Research Council Grant MT-7088.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Supported by studentships from the Medical Research Council of Canada.
§ To whom correspondence should be addressed: Centre de recherche en cancérologie de l'Université Laval, L'Hôtel-Dieu de Québec, 11 côte du Palais, Québec G1R 2J6, Canada. Tel.: 418-691-5555; Fax: 418-691-5439; E-mail: jacques.landry@med.ulaval.ca.
2 T. C. Wu and R. M. Tanguay, unpublished data.
3 K. Bellmann, V. Burkart, H. Bruckhoff, H. Kolb, and J. Landry, manuscript in preparation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: HSP(s), heat shock protein(s); MAP kinase, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; SAPK, stress-activated protein kinase; JNK, Jun N-terminal kinase; EGF, epidermal growth factor; TNF, tumor necrosis factor; GST, glutathione S-transferase; HA, hemagglutinin; MOPS, 4-morpholinepropanesulfonic acid; MAPKAP, MAP-activated protein; ATF2, activating transcription factor-2.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Wu, C., Clos, J., Giorgi, G., Haroun, R. I., Kim, S.-J., Rabindran, S. K., Westwood, J. T., Wisniewski, J., and Yim, G. (1994) in The Biology of Heat Shock Proteins and Molecular Chaperones (Morimoto, R. I. , Tissières, A. , and Georgopoulos, C., eds) , pp. 395-416, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 2. | Morimoto, R. I., Jurivich, D. A., Kroeger, P. E., Mathur, S. K., Murphy, S. P., Nakai, A., Sarge, K., Abravaya, K., and Sistonen, L. T. (1994) in The Biology of Heat Shock Proteins and Molecular Chaperones (Morimoto, R. I. , Tissières, A. , and Georgopoulos, C., eds) , pp. 417-456, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 3. |
Morimoto, R. I.
(1998)
Genes Dev.
12,
3788-3796 |
| 4. | Dubois, M. F., and Bensaude, O. (1993) FEBS Lett. 324, 191-195[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Adler, V.,
Schaffer, A.,
Kim, J.,
Dolan, L.,
and Ronai, Z.
(1995)
J. Biol. Chem.
270,
26071-26077 |
| 6. | Rouse, J., Cohen, P., Trigon, S., Morange, M., Alonso-Llamazares, A., Zamanillo, D., Hunt, T., and Nebreda, A. R. (1994) Cell 78, 1027-1037[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Gerner, E. W., and Schneider, M. J. (1975) Nature 256, 500-503[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Landry, J.,
Bernier, D.,
Chrétien, P.,
Nicole, L. M.,
Tanguay, R. M.,
and Marceau, N.
(1982)
Cancer Res.
42,
2457-2461 |
| 9. |
Li, G. C.,
and Werb, Z.
(1982)
Proc. Natl. Acad. Sci. U. S. A.
79,
3218-3222 |
| 10. | Landry, J., Chrétien, P., Laszlo, A., and Lambert, H. (1991) J. Cell. Physiol. 147, 93-101[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Landry, J.,
Chrétien, P.,
Lambert, H.,
Hickey, E.,
and Weber, L. A.
(1989)
J. Cell Biol.
109,
7-15 |
| 12. |
Li, G. C.,
Li, L. G.,
Liu, Y. K.,
Mak, J. Y.,
Chen, L. L.,
and Lee, W. M.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1681-1685 |
| 13. | Angelidis, C. E., Lazaridis, I., and Pagoulatos, G. N. (1991) Eur. J. Biochem. 199, 35-39[Medline] [Order article via Infotrieve] |
| 14. |
Lavoie, J. N.,
Gingras-Breton, G.,
Tanguay, R. M.,
and Landry, J.
(1993)
J. Biol. Chem.
268,
3420-3429 |
| 15. |
Huot, J.,
Roy, G.,
Lambert, H.,
Chrétien, P.,
and Landry, J.
(1991)
Cancer Res.
51,
5245-5252 |
| 16. | Jäättelä, M., Wissing, D., Bauer, P. A., and Li, G. C. (1992) EMBO J. 11, 3507-3512[Medline] [Order article via Infotrieve] |
| 17. | Mehlen, P., Preville, X., Chareyron, P., Briolay, J., Klemenz, R., and Arrigo, A. P. (1995) J. Immunol. 154, 363-374[Abstract] |
| 18. |
Huot, J.,
Houle, F.,
Spitz, D. R.,
and Landry, J.
(1996)
Cancer Res.
56,
273-279 |
| 19. |
Mehlen, P.,
Schulze-Osthoff, K.,
and Arrigo, A. P.
(1996)
J. Biol. Chem.
271,
16510-16514 |
| 20. | Bellmann, K., Jäättelä, M., Wissing, D., Burkart, V., and Kolb, H. (1996) FEBS Lett. 391, 185-188[CrossRef][Medline] [Order article via Infotrieve] |
| 21. |
Garrido, C.,
Ottavi, P.,
Fromentin, A.,
Hammann, A.,
Arrigo, A. P.,
Chauffert, B.,
and Mehlen, P.
(1997)
Cancer Res.
57,
2661-2667 |
| 22. | Guenal, I., Sidoti-de Fraisse, C., Gaumer, S., and Mignotte, B. (1997) Oncogene 15, 347-360[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Buzzard, K. A.,
Giaccia, A. J.,
Killender, M.,
and Anderson, R. L.
(1998)
J. Biol. Chem.
273,
17147-17153 |
| 24. | Jäättelä, M., Wissing, D., Kokholm, K., Kallunki, T., and Egeblad, M. (1998) EMBO J. 17, 6124-6134[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Wagstaff, M. J.,
Collaco-Moraes, Y.,
Smith, J.,
de Belleroche, J. S.,
Coffin, R. S.,
and Latchman, D. S.
(1999)
J. Biol. Chem.
274,
5061-5069 |
| 26. |
Xia, Z.,
Dickens, M.,
Raingeaud, J.,
Davis, R. J.,
and Greenberg, M. E.
(1995)
Science
270,
1326-1331 |
| 27. |
Zechner, D.,
Craig, R.,
Hanford, D. S.,
McDonough, P. M.,
Sabbadini, R. A.,
and Glembotski, C. C.
(1998)
J. Biol. Chem.
273,
8232-8239 |
| 28. |
Nemoto, S.,
Xiang, J.,
Huang, S.,
and Lin, A.
(1998)
J. Biol. Chem.
273,
16415-16420 |
| 29. |
Roulston, A.,
Reinhard, C.,
Amiri, P.,
and Williams, L. T.
(1998)
J. Biol. Chem.
273,
10232-10239 |
| 30. | Huot, J., Lambert, H., Lavoie, J. N., Guimond, A., Houle, F., and Landry, J. (1995) Eur. J. Biochem. 227, 416-427[Medline] [Order article via Infotrieve] |
| 31. |
Lambert, H.,
Charette, S. J.,
Bernier, A. F.,
Guimond, A.,
and Landry, J.
(1999)
J. Biol. Chem.
274,
9378-9385 |
| 32. |
Benndorf, R.,
Hayess, K.,
Ryazantsev, S.,
Wieske, M.,
Behlke, J.,
and Lutsch, G.
(1994)
J. Biol. Chem.
269,
20780-20784 |
| 33. | Lavoie, J. N., Lambert, H., Hickey, E., Weber, L. A., and Landry, J. (1995) Mol. Cell. Biol. 15, 505-516[Abstract] |
| 34. | Guay, J., Lambert, H., Gingras-Breton, G., Lavoie, J. N., Huot, J., and Landry, J. (1997) J. Cell Sci. 110, 357-368[Abstract] |
| 35. | Landry, J., and Huot, J. (1999) Biochem. Soc. Symp. 64, 79-89[Medline] [Order article via Infotrieve] |
| 36. |
Huot, J.,
Houle, F.,
Rousseau, S.,
Deschesnes, R. G.,
Shah, G. M.,
and Landry, J.
(1998)
J. Cell Biol.
143,
1361-1373 |
| 37. |
Landry, J.,
Lambert, H.,
Zhou, M.,
Lavoie, J. N.,
Hickey, E.,
Weber, L. A.,
and Anderson, C. W.
(1992)
J. Biol. Chem.
267,
794-803 |
| 38. |
Dérijard, B.,
Raingeaud, J.,
Barrett, T.,
Wu, I.-H.,
Han, J.,
Ulevitch, R. J.,
and Davis, R. J.
(1995)
Science
267,
682-684 |
| 39. | Tanguay, R. M., Wu, Y., and Khandjian, E. W. (1993) Dev. Genet. 14, 112-118[CrossRef][Medline] [Order article via Infotrieve] |
| 40. |
Mosser, D. D.,
Duchaine, J.,
and Massie, B.
(1993)
Mol. Cell. Biol.
13,
5427-5438 |
| 41. | Berra, E., Municio, M. M., Sanz, L., Frutos, S., Diaz-Meco, M. T., and Moscat, J. (1997) Mol. Cell. Biol. 17, 4346-4354[Abstract] |
| 42. |
Hickey, E.,
Brandon, S. E.,
Smale, G.,
Lloyd, D.,
and Weber, L. A.
(1989)
Mol. Cell. Biol.
9,
2615-2626 |
| 43. | Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., and Lee, J. C. (1995) FEBS Lett. 364, 229-233[CrossRef][Medline] [Order article via Infotrieve] |
| 44. |
Meriin, A. B.,
Gabai, V. L.,
Yaglom, J.,
Shifrin, V. I.,
and Sherman, M. Y.
(1998)
J. Biol. Chem.
273,
6373-6379 |
| 45. |
Widmann, C.,
Gibson, S.,
Jarpe, M. B.,
and Johnson, G. L.
(1999)
Physiol. Rev.
79,
143-180 |
| 46. | Raingeaud, J., Whitmarsh, A. J., Barrett, T., Dérijard, B., and Davis, R. J. (1996) Mol. Cell. Biol. 16, 1247-1255[Abstract] |
| 47. |
Han, J.,
Lee, J. D.,
Jiang, Y.,
Li, Z.,
Feng, L.,
and Ulevitch, R. J.
(1996)
J. Biol. Chem.
271,
2886-2891 |
| 48. |
Moriguchi, T.,
Kuroyanagi, N.,
Yamaguchi, K.,
Gotoh, Y.,
Irie, K.,
Kano, T.,
Shirakabe, K.,
Muro, Y.,
Shibuya, H.,
Matsumoto, K.,
Nishida, E.,
and Hagiwara, M.
(1996)
J. Biol. Chem.
271,
13675-13679 |
| 49. | Tibbles, L. A., Ing, Y. L., Kiefer, F., Chan, J., Iscove, N., Woodgett, J. R., and Lassam, N. J. (1996) EMBO J. 15, 7026-7035[Medline] [Order article via Infotrieve] |
| 50. |
Ichijo, H.,
Nishida, E.,
Irie, K.,
ten-Dijke, P.,
Saitoh, M.,
Moriguchi, T.,
Takagi, M.,
Matsumoto, K.,
Miyazono, K.,
and Gotoh, Y.
(1997)
Science
275,
90-94 |
| 51. | Cuenda, A., and Dorow, D. S. (1998) Biochem. J. 333, 11-15 |
| 52. |
Chang, H. Y.,
Nishitoh, H.,
Yang, X.,
Ichijo, H.,
and Baltimore, D.
(1998)
Science
281,
1860-1863 |
| 53. | Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., and Ichijo, H. (1998) EMBO J. 17, 2596-2606[CrossRef][Medline] [Order article via Infotrieve] |
| 54. |
Anafi, M.,
Kiefer, F.,
Gish, G. D.,
Mbamalu, G.,
Iscove, N. N.,
and Pawson, T.
(1997)
J. Biol. Chem.
272,
27804-27811 |
| 55. |
Zhou, G.,
Lee, S. C.,
Yao, Z.,
and Tan, T. H.
(1999)
J. Biol. Chem.
274,
13133-13138 |
| 56. |
Yao, Z.,
Zhou, G.,
Wang, X. S.,
Brown, A.,
Diener, K.,
Gan, H.,
and Tan, T. H.
(1999)
J. Biol. Chem.
274,
2118-2125 |
| 57. |
Yamauchi, J.,
Nagao, M.,
Kaziro, Y.,
and Itoh, H.
(1997)
J. Biol. Chem.
272,
27771-27777 |
| 58. | Mosser, D. D., Caron, A. W., Bourget, L., Denis-Larose, C., and Massie, B. (1997) Mol. Cell. Biol. 17, 5317-5327[Abstract] |
| 59. |
Gabai, V. L.,
Meriin, A. B.,
Mosser, D. D.,
Caron, A. W.,
Rits, S.,
Shifrin, V. I.,
and Sherman, M. Y.
(1997)
J. Biol. Chem.
272,
18033-18037 |
| 60. |
Gotoh, Y.,
and Cooper, J. A.
(1998)
J. Biol. Chem.
273,
17477-17482 |
| 61. |
Rosette, C.,
and Karin, M.
(1996)
Science
274,
1194-1197 |
| 62. |
Lin, R. Z.,
Hu, Z. W.,
Chin, J. H.,
and Hoffman, B. B.
(1997)
J. Biol. Chem.
272,
31196-31202 |
| 63. | Sachsenmaier, C., Radler-Pohl, A., Zinck, R., Nordheim, A., Herrlich, P., and Rahmsdorf, H. J. (1994) Cell 78, 963-972[CrossRef][Medline] [Order article via Infotrieve] |
| 64. | Green, D., and Kroemer, G. (1998) Trends Cell Biol. 8, 267-271[CrossRef][Medline] [Order article via Infotrieve] |
| 65. | Juo, P., Kuo, C. J., Yuan, J., and Blenis, J. (1998) Curr. Biol. 8, 1001-1008[CrossRef][Medline] [Order article via Infotrieve] |
| 66. | Cardone, M. H., Salvesen, G. S., Widmann, C., Johnson, G., and Frisch, S. M. (1997) Cell 90, 315-323[CrossRef][Medline] [Order article via Infotrieve] |
| 67. | Lee, D. H., and Goldberg, A. L. (1998) Trends Cell Biol. 8, 397-403[CrossRef][Medline] [Order article via Infotrieve] |
| 68. | Parag, H. A., Raboy, B., and Kulka, R. G. (1987) EMBO J. 6, 55-61[Medline] [Order article via Infotrieve] |
| 69. |
Carlson, N.,
Rogers, S.,
and Rechsteiner, M.
(1987)
J. Cell Biol.
104,
547-555 |
| 70. | Hickey, E. D., and Weber, L. A. (1982) Biochemistry 21, 1513-1521[CrossRef][Medline] [Order article via Infotrieve] |
| 71. |
Fornace, A. J., Jr.,
Alamo, I., Jr.,
Hollander, M. C.,
and Lamoreaux, E.
(1989)
Nucleic Acids Res.
17,
1215-1230 |
| 72. |
Bercovich, B.,
Stancovski, I.,
Mayer, A.,
Blumenfeld, N.,
Laszlo, A.,
Schwartz, A. L.,
and Ciechanover, A.
(1997)
J. Biol. Chem.
272,
9002-9010 |
| 73. |
Imamura, T.,
Haruta, T.,
Takata, Y.,
Usui, I.,
Iwata, M.,
Ishihara, H.,
Ishiki, M.,
Ishibashi, O.,
Ueno, E.,
Sasaoka, T.,
and Kobayashi, M.
(1998)
J. Biol. Chem.
273,
11183-11188 |
This article has been cited by other articles:
![]() |
N. Yamamoto, H. Sawada, Y. Izumi, T. Kume, H. Katsuki, S. Shimohama, and A. Akaike Proteasome Inhibition Induces Glutathione Synthesis and Protects Cells from Oxidative Stress: RELEVANCE TO PARKINSON DISEASE J. Biol. Chem., February 16, 2007; 282(7): 4364 - 4372. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dorion, H. Lambert, and J. Landry Activation of the p38 Signaling Pathway by Heat Shock Involves the Dissociation of Glutathione S-Transferase Mu from Ask1 J. Biol. Chem., August 16, 2002; 277(34): 30792 - 30797. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Luss, W. Schmitz, and J. Neumann A proteasome inhibitor confers cardioprotection Cardiovasc Res, April 1, 2002; 54(1): 140 - 151. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||